[

• Tác giả: Manon Allaire, Giuliana Amaddeo, Florent L Besson, Coralie Bloch-Queyrat, Mohamed Bouattour, Marouane Boubaya, Julia Chalaye, Audrey Coilly, Charlotte Costentin, Marco Dioguardi Burgio, Anthony Dohan, Nathalie Ganne-Carrié, Denis Mariano Goulart, Boris Guiu, Clémence Hollande, Emmanuel Itti, Rachida Lebtahi, Marie Lequoy, Vincent Levy, Maïté Lewin, Alain Luciani, Philippe Maksud, Yves Menu, Françoise Montravers, Sebastien Mulé, Pierre Nahon, Jean-Charles Nault, Georges-Philippe Pageaux, Stanislas Pol, Gabriel Pop, Hélène Regnault, Maxime Ronot, Julie Roux, Christian Sengel, Sabrina Sidali, Michael Soussan, Olivier Sutter, Mathilde Wagner, Myriam Wartski
• Ngôn ngữ: eng
• Thông tin xuất bản: Netherlands : The lancet. Gastroenterology & hepatology , 2025
• Bộ sưu tập: NCBI
• ID: 643640

Tóm tắt

BACKGROUND: The role of PET-CT with [ METHODS: We conducted a multicentre prospective study (PET-HCC01) in nine hospitals in France, including patients aged 18 years or older with a first diagnosis of hepatocellular carcinoma classified as Barcelona Clinic Liver Cancer (BCLC) classification A to C (without metastasis). At study inclusion, patients underwent contrast-enhanced liver MRI and liver, chest, and pelvis CT scans. Patients subsequently underwent [ FINDINGS: Between July 20, 2020, and April 27, 2023, 230 patients were enrolled. Among the 215 patients included in the intention-to-image population, the median age was 66·0 years (IQR 60·0-71·5), 193 (90%) were male, and 155 (73%) had cirrhosis. Hepatocellular carcinoma was classified as BCLC stage A in 140 (65%) patients, B in 48 (22%), and C without metastasis in 27 (13%) on the basis of morphological imaging. Potential new lesions were identified in 19 (9%) patients by PET-CT (eight by both tracers, six by [ INTERPRETATION: [ FUNDING: Programme Hospitalier de Recherche Clinique Inter-regional-PHRC-I2018 (Ministère de la Santé).